Point of Care Testing Market Size, Share and Forecast 2025–2035
What Is the Point of Care Testing Market Size?
The global Point of Care Testing market was valued at USD 62.7 Billion in 2025 and is projected to grow from USD 67.5 Billion in 2026 to USD 131.6 Billion by 2035, at a CAGR of 7.7% from 2026–2035.
Point of Care Testing Market Key Takeaways
According to Healthcare Industry Insights analysis, brand owners and enterprise buyers are increasingly consolidating vendor sourcing with fewer, certification-ready suppliers to simplify multi-region regulatory compliance, a shift that favors diversified manufacturers over single-region specialists as regulatory scrutiny intensifies through 2035.
What Does the Point of Care Testing Market Encompass?
The point of care testing market covers diagnostic tests performed near the patient, outside central laboratories. It spans handheld and benchtop analyzers, single-use reagent cartridges, and connectivity software that transmits results to electronic health records. Primary application areas include chronic disease monitoring, infectious disease detection, critical care, and home or pharmacy-based self-testing.
The technical scope includes microfluidic sensors, lateral flow and molecular cartridges, and quality control materials that ensure accurate results at the bedside. Products must meet regulatory requirements such as CLIA waiver criteria in the United States, the EU In Vitro Diagnostic Regulation, and accreditation standards for laboratory and point-of-care testing. Safety, calibration, and operator competency rules shape how devices are validated and deployed across care settings.
| Parameter | Details |
|---|---|
| Market Size in 2025 | USD 62.7 Billion |
| Market Size in 2026 | USD 67.5 Billion |
| Revenue Forecast in 2035 | USD 131.6 Billion |
| Growth Rate | CAGR of 7.7% from 2026 to 2035 |
| Analysis Period | 2025–2035 |
| Base Year Considered | 2025 |
| Forecast Period | 2026–2035 |
| Market Size Estimation | Revenue (USD Billion) |
| Companies Profiled | 20 Profiled |
| Countries Covered | 15 Countries |
| Market Share | Available for Top 10 Companies |
Key Emerging Trends in the Point of Care Testing Market
Based on research conducted by Healthcare Industry Insights, we found that four structural trends are reshaping product development, sourcing, and stakeholder engagement across the Point of Care Testing industry.
Growth Drivers, Restraints & Opportunities
The following interactive matrix outlines the primary forces shaping the Point of Care Testing market through 2035.0, categorized by qualitative impact level, geographic relevance, and projected timeline. Type in the search box to filter by driver, restraint, or opportunity.
| Factors ▲ | Type | Qualitative Impact | Geographic Focus | Timeline |
|---|---|---|---|---|
| Dense reimbursement frameworks and CLIA-waived test menus | DRIVER | High | North America | Short term |
| Rising chronic disease prevalence requiring routine monitoring | DRIVER | High | Global | Long term |
| Public-sector infectious disease and maternal-health screening programs | DRIVER | Medium | Latin America, Asia-Pacific | Medium term |
| Primary-care network expansion in China, India, and Japan | DRIVER | Medium | Asia-Pacific | Medium term |
| Tighter EU IVDR regulatory timelines | RESTRAINT | Medium | Europe | Medium term |
| Currency volatility and fragmented procurement | RESTRAINT | Medium | Latin America | Short term |
| Limited laboratory infrastructure and funding constraints | RESTRAINT | High | Middle East & Africa | Long term |
How Do Reimbursement Frameworks Anchor Baseline Demand?
Reimbursement rules in North America create a stable demand floor for point of care testing. Mandated and reimbursed test menus support hardware placements and recurring cartridge purchases. This baseline anchors volume, but it grows more slowly than emerging application segments.
Which Factors Act as the Main Growth Engines?
Chronic disease monitoring, self-testing, and connectivity platforms form the primary growth vectors. Home-based self-testing grows at a 12.3% CAGR, while connectivity software grows at 12.7%. Growth engines are concentrated in high-CAGR emerging segments rather than mature reimbursed categories.
What Constrains Expansion in Emerging Regions?
Limited laboratory infrastructure, funding gaps, and currency volatility slow adoption in Latin America and Middle East & Africa. Procurement fragmentation raises the cost of entry for device makers. Middle East & Africa is projected to grow at a 2.9% CAGR over the 2026–2035 forecast period, the slowest among regions.
Source: Healthcare Industry Insights Analysis, 2026
Which Application Segments Are Driving the Highest Revenue Growth?
Segment Sizing: By Offering
Within the By Offering category, the Handheld and Benchtop POC Analyzer Hardware (Cartridge Readers, Sensors, Microfluidic Devices) segment held the dominant market share in 2025. Meanwhile, the Connectivity Software, Data Integration, and Clinical Decision Algorithms segment is anticipated to be the fastest-growing, expanding at a CAGR of 12.7% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| Handheld and Benchtop POC Analyzer Hardware (Cartridge Readers, Sensors, Microfluidic Devices) | 36.4 | 38.3 | 60.5 | 5.2% |
| Consumables and Reagent Test Cartridges/Strips | 19.4 | 21.3 | 48.0 | 9.4% |
| Connectivity Software, Data Integration, and Clinical Decision Algorithms | 6.9 | 7.9 | 23.1 | 12.7% |
| Total | 62.7 | 67.5 | 131.6 | 7.7% |
Source: Healthcare Industry Insights Analysis, 2026
Segment Sizing: By Application
Within the By Application category, the Glycemic, Metabolic, and Chronic Disease Monitoring (Glucose, HbA1c, Lipids, Coagulation) segment held the dominant market share in 2025. Meanwhile, the Home-Based, Telehealth-Linked, and Pharmacy-Retail Self-Testing segment is anticipated to be the fastest-growing, expanding at a CAGR of 12.3% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| Glycemic, Metabolic, and Chronic Disease Monitoring (Glucose, HbA1c, Lipids, Coagulation) | 21.3 | 22.6 | 38.2 | 6.0% |
| Infectious Disease and Respiratory Pathogen Detection (Influenza, COVID-19, Strep, STI) | 16.9 | 18.2 | 34.2 | 7.3% |
| Critical Care and Emergency Diagnostics (Blood Gas, Electrolytes, Troponin, Coagulation) | 15.0 | 16.1 | 29.0 | 6.8% |
| Home-Based, Telehealth-Linked, and Pharmacy-Retail Self-Testing | 9.5 | 10.6 | 30.2 | 12.3% |
| Total | 62.7 | 67.5 | 131.6 | 7.7% |
Source: Healthcare Industry Insights Analysis, 2026
Segment Sizing: By End-User
Within the By End-User category, the Hospitals, Emergency Departments, and Intensive Care Units segment held the dominant market share in 2025. Meanwhile, the Ambulatory Clinics, Physician Offices, Urgent Care, and Retail Pharmacies segment is anticipated to be the fastest-growing, expanding at a CAGR of 9.8% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| Hospitals, Emergency Departments, and Intensive Care Units | 28.8 | 30.6 | 52.6 | 6.2% |
| Ambulatory Clinics, Physician Offices, Urgent Care, and Retail Pharmacies | 20.7 | 22.7 | 52.6 | 9.8% |
| Home Users, Caregivers, and Remote Telehealth Patients | 13.2 | 14.2 | 26.4 | 7.1% |
| Total | 62.7 | 67.5 | 131.6 | 7.7% |
Source: Healthcare Industry Insights Analysis, 2026
Key Market Segments
The complete segmentation hierarchy used throughout this report. Click a category to view its sub-segments.
Growth Opportunities
Our analysis shows that three forward-looking opportunities stand out for stakeholders positioning within this market over the forecast period.
Where Can Vendors Capture Recurring Cartridge Revenue Beyond Hardware?
Consumables are forecast to climb to USD 48 Billion by 2035. Vendors with broad, CLIA-waived cartridge menus can lock in repeat purchases. Expanding menus into chronic and infectious panels offers a practical route to share gains.
How Can Pharmacy and Telehealth Channels Open New Patient Access?
Retail pharmacies and telehealth platforms can extend testing to patients outside clinics. Self-testing is the fastest-growing application at 12.3%. Partnerships with pharmacy chains and virtual care providers can reach this demand efficiently.
Which Emerging Markets Offer Low-Cost Localization Potential?
India, China, and Japan are building domestic rapid diagnostic capacity. Local manufacturing can serve primary-care networks at lower prices. Asia-Pacific is the fastest-gaining region at an 11.0% CAGR.
Investment Opportunities
Capital Inflows
Capital is flowing toward consolidation and platform acquisitions. Recent transactions show buyers pursuing scale in cartridge and analyzer portfolios. Investors are focusing on companies with recurring consumable revenue.
Infrastructure
Decentralized testing requires connectivity, data integration, and distribution networks. Investment in software and logistics supports the shift from central labs to pharmacies and homes. Infrastructure spending supports the 12.7% connectivity growth outlook.
ESG
Shorter testing journeys and reduced sample transport lower the carbon footprint of diagnostics. Sustainable cartridge packaging and waste reduction are gaining attention from procurement teams. ESG-aligned suppliers may gain preference in public tenders.
SWOT Analysis
Our assessment indicates that the following strengths, weaknesses, opportunities, and threats characterize the competitive position of the Point of Care Testing heading into 2035.
Installed analyzer bases and CLIA-waived menus give leading vendors durable recurring revenue. Broad regulatory clearance pathways support rapid product launches in major markets.
Fragmented procurement and currency volatility in Latin America complicate contract planning. Limited laboratory infrastructure restricts uptake across sub-Saharan Africa.
Self-testing and connectivity platforms carry the highest CAGRs at 12.3% and 12.7%. Asia-Pacific expansion and domestic manufacturing offer large volume gains.
Tighter EU IVDR timelines raise compliance costs for smaller manufacturers. Pricing pressure from low-cost regional producers may compress margins in high-volume segments.
Access the Full Market Report
15 Countries · 20 Profiled · 10-year forecast with YoY data tables · Free Excel data file included
Regional Outlook
Click a region to explore its key national markets and growth drivers.
North America was valued at USD 26.01 Billion in 2025 and estimated at USD 27.72 Billion in 2026, reaching USD 48.66 Billion by 2035 at a 6.5% CAGR (2026–2035). Reimbursement depth and CLIA-waived menus sustain the largest revenue base. Share erodes gradually as Asian suppliers scale faster.
United States
CanadaEurope was valued at USD 16.9 Billion in 2025 and estimated at USD 18.1 Billion in 2026, reaching USD 33.6 Billion by 2035 at a 7.1% CAGR (2026–2035). National near-patient testing programs in the UK, Germany, and France provide steady demand. IVDR compliance is consolidating manufacturers toward larger platforms.
Germany
United Kingdom
FranceAsia-Pacific was valued at USD 13.2 Billion in 2025 and estimated at USD 14.7 Billion in 2026, reaching USD 37.5 Billion by 2035 at a 11.0% CAGR (2026–2035). Primary-care expansion in China, India, and Japan drives volume. Domestic rapid diagnostic manufacturing is lowering unit prices across the region.
China
India
Japan
South Korea
AustraliaLatin America was valued at USD 3.45 Billion in 2025 and estimated at USD 3.73 Billion in 2026, reaching USD 7.63 Billion by 2035 at a 8.3% CAGR (2026–2035). Public HIV, tuberculosis, and maternal screening programs anchor adoption. Currency swings and fragmented tenders limit how quickly spending scales.
Brazil
ArgentinaMiddle East & Africa was valued at USD 3.14 Billion in 2025 and estimated at USD 3.25 Billion in 2026, reaching USD 4.21 Billion by 2035 at a 2.9% CAGR (2026–2035). Gulf healthcare investment supports diagnostic localization. Sub-Saharan funding gaps and thin laboratory networks keep growth the slowest of all regions.
Saudi Arabia
UAE
South AfricaCompetitive Landscape
Large players compete on cartridge menus and installed analyzer footprints. Their scale supports broad regulatory filings across multiple countries. Smaller specialists focus on niche assays and rapid platforms.
Point of Care Testing Competitive Insights
| Dimension | Description |
|---|---|
| Market Structure | Moderately consolidated, with large diagnostics groups alongside specialist analyzer makers |
| Innovation Focus | Connectivity software, molecular cartridges, and handheld immunodiagnostic platforms |
| M&A Activity | Active consolidation, including the GH Solutions acquisition and the Waters and BD business combination |
Source: Healthcare Industry Insights Analysis, 2026
Portfolio Breadth Among Diagnostics Leaders
Large players compete on cartridge menus and installed analyzer footprints. Their scale supports broad regulatory filings across multiple countries. Smaller specialists focus on niche assays and rapid platforms.
Consolidation Reshaping Supplier Scale
Recent transactions are concentrating capabilities among fewer groups. Acquisitions add long-term customers and manufacturing depth. This trend raises barriers for sub-scale entrants.
Connectivity as a Differentiator
Vendors are bundling middleware, data integration, and audit tools with devices. These features lock in customers through software ecosystems. Connectivity is becoming as important as analytical accuracy.
Regional Competitive Pressure
Asian manufacturers are pressing on price in high-volume segments. European firms are adapting portfolios to IVDR requirements. Competitive intensity varies by region and regulatory environment.
Key Market Players in the Point of Care Testing
Key companies active in the global Point of Care Testing include:
Latest Point of Care Testing Industry Developments
We found that recent product launches within the Point of Care Testing are concentrated on key technological advancements, reflecting the industry's broader transition.
| Date | Summary | Source |
|---|---|---|
| August 2026 | HealthTab entered a multi-year collaboration agreement with Abbott for point-of-care testing across the UK. | Official Press Release |
| June 2026 | Proxim Diagnostics achieved its final system development milestone for a handheld point-of-care immunodiagnostic platform. | Official Announcement |
| April 2026 | Premier Biotech acquired GH Solutions, adding meaningful long-term customers to its point-of-care testing business. | Official Announcement |
| April 2026 | TTP Group announced the sale of LEX Diagnostics, a molecular point-of-care testing company. | Official Announcement |
| February 2026 | Waters completed its combination with the BD Biosciences and Diagnostic Solutions businesses. | Official Press Release |
Source: Healthcare Industry Insights Analysis, 2026
Expert Insights: Point of Care Testing
Through our market assessment, we gathered perspectives from senior executives active in the point of care testing ecosystem.
Market Interpretation
This statement signals that Waters is prioritizing customer needs during its integration with the BD diagnostic businesses. For point of care testing, that focus likely centers on analyzer reliability, cartridge menu continuity, and service coverage across hospitals and clinics. Our assessment indicates that vendors able to align integration milestones with customer workflows will protect installed bases and sustain recurring consumable revenue through the forecast period.
Key Benefits for Point of Care Testing Stakeholders
Stakeholder
Enterprise leaders gain faster clinical decisions and reduced reliance on central laboratory turnaround. Standardized connectivity improves audit readiness. Broad test menus allow care teams to address more conditions at the point of need.
Stakeholder
Investors can access a market expanding from USD 62.7 Billion to USD 131.6 Billion. Recurring consumable revenue offers predictable cash flow. Emerging-market growth in Asia-Pacific adds diversification beyond mature North American demand.
Stakeholder
Technology vendors can expand into middleware, data integration, and clinical algorithms. Software-led offerings are the fastest-growing offering category. Partnerships with analyzer makers create durable distribution channels.
Conclusion and Recommendations
Long-Term Outlook
The market is set to more than double between 2026 and 2035. Decentralized testing and connectivity will shape growth. Reimbursed hardware provides a stable base while emerging segments drive expansion.
Strategic Positioning Recommendations
Vendors should prioritize cartridge menus and connectivity platforms. Partnerships with pharmacies and telehealth providers can extend reach. Investment should target Asia-Pacific and self-testing channels.
Investment Attractiveness
Recurring consumable revenue and rising software attach rates make the sector attractive. Consolidation offers entry through acquisition. Investors should weigh regulatory timelines in Europe and funding constraints in emerging regions.
Market Shifts and Key Risks
Shifts toward home and retail testing will alter distribution models. Regulatory tightening in Europe and price pressure from regional manufacturers pose risks. Procurement fragmentation in Latin America remains a challenge.
Growth Pathways
Mandated and reimbursed categories anchor baseline demand. High-CAGR segments such as self-testing and connectivity software are the primary growth pathways. Absolute dollar opportunity of USD 64.1 Billion between 2026 and 2035 rewards early positioning.
Frequently Asked Questions
Consolidated Source Table
Methodology Note: Market sizing figures are HII industry-derived estimates based on triangulated supply-side manufacturer revenue analysis, demand-side consumption assessment, and macro-level trade and investment tracking across publicly available corporate disclosures, government statistics, and regulatory filings. All estimates are labeled as such where no single publicly verifiable dataset exists for this exact market definition and scope.
Summarize This Report:
You May Also Like
Risk Evaluation and Mitigation Strategy (REMS) Services Market
eClinical Solutions Market
Structural Biology Services Market
Psychobiotic Market
Tyrosine Kinase Inhibitor Market
Antibody Drug Conjugate Market
Custom Market Research Services
We will customise the research for you, in case the report listed above does not meet with your exact requirements. Get 30% free customisation on this report.